Alan Epstein, MD
Rheumatology · Philadelphia, PANPI 1346211844
Payments from drug & device makers
Across 1,554 payments — averaging $745.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$199K
- AbbVie$181K
- Lilly USA, LLC$164K
- Amgen$109K
- AstraZeneca$97K
- GSK$70K
- plus $340K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 128 | $198,915 |
| AbbVie(2 entities) | 296 | $180,741 |
| Lilly USA, LLC | 289 | $163,762 |
| Amgen(2 entities) | 201 | $108,676 |
| AstraZeneca(2 entities) | 126 | $97,163 |
| GSK | 68 | $69,703 |
| Regeneron Healthcare Solutions, Inc. | 78 | $62,711 |
| Johnson & Johnson(2 entities) | 82 | $61,404 |
| Janssen Scientific Affairs, LLC | 58 | $57,867 |
| Pfizer | 73 | $38,672 |
| Novartis | 32 | $30,328 |
| United Rheumatology | 5 | $28,900 |
| E.r. Squibb & Sons, L.L.C. | 42 | $24,248 |
| Sandoz | 6 | $9,751 |
| Fresenius Kabi USA, LLC | 3 | $6,925 |
| Gilead | 10 | $5,643 |
| UCB, Inc. | 21 | $5,094 |
| Sobi, Inc | 4 | $2,810 |
| Boehringer Ingelheim | 5 | $2,232 |
| Invivyd Inc | 1 | $2,013 |
| Eli Lilly | 2 | $775 |
| Aurinia Pharma U.S., Inc. | 6 | $479 |
| Sanofi-aventis U.S. LLC | 2 | $144 |
| Genentech USA, Inc. | 9 | $133 |
| Regeneron | 1 | $49 |
| Zimmer Biomet | 1 | $30 |
| Merck | 2 | $23 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Medexus Pharma, Inc. | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $12 |
How this compares
$1,159,236 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Philadelphia
- Alexis Ogdie-BeattyPhiladelphia$5.7M
- Jonathan MinerPhiladelphia$3.8M
- Fabian Mendoza BallesterosPhiladelphia$564K
- James UdellPhiladelphia$516K
- Nora SandorfiPhiladelphia$445K
- Michael GeorgePhiladelphia$367K
- Shubhasree BanerjeePhiladelphia$348K
- Chris DerkPhiladelphia$243K
- Bruce HoffmanPhiladelphia$141K
- Philip CohenPhiladelphia$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.